Overview

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Status:
Enrolling by invitation

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.

Phase:

Early Phase 1

Details

Lead Sponsor:

Sandeep Laroia

Collaborators:

Holden Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health (NIH)

Treatments:

Edotreotide
Octreotide